Isomorphic Labs seeks funding at a valuation of $40 billion or more

Oct 8, 2026

AI Summary

Isomorphic Labs, a startup focused on AI-driven drug discovery, is in discussions to secure new funding that could value the company at a minimum of $40 billion. The potential valuation may rise to $50 billion, though the financing details are still being finalized.

Isomorphic Labs is a startup that emerged from Alphabet's Google DeepMind, specializing in AI-powered drug discovery.
The company is currently in early talks to raise new funds, aiming for a valuation of at least $40 billion.
There is potential for the valuation to reach as high as $50 billion, but the financing has not yet been finalized and details may change.
Isomorphic Labs has not provided comments regarding the funding discussions.

isomorphic labsdrug discoveryfundingalphabetdeepmind

Isomorphic Labs seeks funding at a valuation of $40 billion or more

Related Stories

OpenAI Revises Revenue Projections, Delta Air Lines Misses Earnings Estimates, and Starbucks Considers Chipotle Acquisition

Revolut CEO outlines plans to expand digital banking services in the US

Bending Spoons CEO Highlights Acquisition Opportunities Amid Software Valuation Declines

AI Competition Shifts Focus to Financing Strategies Amid Technology Developments